AbbVie to buy oncology drug-maker Stemcentrx for at least $5.8B
The centerpiece of Stemcentrx's work is rovalpituzumab tesirine (Rova-T), a biomarker-specific therapy derived from cancer stem cells that is in registrational trials to treat small-cell lung cancer.